LARVOL, Pharma and Oncology SaaS Platforms Provider, to:
· Present clinical research poster at ASCO
· Host virtual reality-based “Night at the Museum” event recognizing top oncologist influencers at ASCO and overall for 2021
· Host clinical panel series: “Understanding #ASCO21: Insights from Expert Oncologists”
San Francisco, CA (May 20, 2021) – BUSINESS WIRE – LARVOL, the leading provider of data and intelligence solutions for the oncology, pharmaceutical, and biotech industries, today announced a full line-up of activities during the 2021American Society of Clinical Oncology Virtual Annual Meeting (ASCO)*. LARVOL will present its poster and host events to both recognize top oncology influencers and curate expert insights from ASCO sessions.
The LARVOL poster titled, “Control arm heterogeneity in trials for unselected advanced triple-negative breast cancer” will be available via On-Demand streaming on Friday June 4 at 9 AM EST. This study explores the application of LARVOL’s clinical data, CLIN, in assessing heterogeneity in control arm time-to-event outcomes. CLIN provides researchers and physicians access to more than 5,000 curated immuno-oncology clinical trials and over20,000 exhibits, allowing them to search and analyze data across all clinical trials within a specific cancer type. CLIN digitizes all tables, graphs, and figures from clinical trial research and data released from publications, conferences, and guidelines, resulting in the most up-to-date repository of all available oncology trial data in one platform, in real time. CLIN is set to launch officially during ASCO, but is available here for preview.
“LARVOL’s poster presentation is an exciting recognition of the innovative work LARVOL is doing to collaborate with oncology thought leaders, curate research and insights and provide researchers access to the universe of clinical trial data to improve the treatment of cancer. CLIN compiled and digitized clinical trial outcomes data that our team applied to this research effort,” said Bruno Larvol, CEO and Founder of LARVOL. Poster details:
Title: Control arm heterogeneity in trials for unselected advanced triple-negative breast cancer
Session Title: Breast Cancer-Metastatic
Abstract ID: 1082
Author List: Kinisha Gala, Ankit Kalucha, Samuel Martinet, Anushri Goel, Kalpana Devi Narisetty, Bruno Larvol, and Kevin Punie, the Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
LARVOL’s “Night at the Museum,” an invitation-only event happening in virtual reality on the final night of ASCO, will bring a museum-like setting to life as LARVOL recognizes key voices in oncology. LARVOL will identify and recognize the Top 100 Influential Oncologists on Twitter for 2021 and the Top 10 ASCO Influencers as curated from LARVOL’s recently launched oncology social listening platform, VIEW. VIEW is the first social listening and sentiment analysis platform focused on Twitter-verified oncologists, researchers, and Digital Opinion Leaders (DOLs). Honorees will be listed on the LARVOL website, post event June 8. A preliminary ranking is available here.
LARVOL will also host a series of five clinical panels throughout the week of ASCO, titled “Understanding #ASCO21:Insights from Expert Oncologists.” The virtual events will bring together two expert oncologists to discuss the topics and research presented at the ASCO sessions in their area of expertise. Panelists will discuss the practice-changing potential of ASCO 2021 abstracts. The event includes 30-minute interviews with KOLs across five therapeutic areas. Attendees, physicians, and journalists are encouraged to join. Participation is free, but participants are asked to register in advance on the LARVOL website.
Featured panelists include:
- Melanoma – June 6, 5:00 PM EST
Allison Betof Warner, MD, PhD (Memorial Sloan Kettering)
Jason Luke, MD (University of Pittsburgh Medical Center)
- Breast Cancer – June 7, 4:30 PMEST
Adam M. Brufsky, MD, PhD(University of Pittsburgh)
William J. Gradishar, MD(Northwestern University)
- Lung Cancer – June 7, 6:00 PMEST
Dr. Sandip Patel(University of California, San Diego)
Dr. Balazs Halmos (Albert Einstein College of Medicine)
- Gastrointestinal Cancer – June 7,7:30 PM EST
Dr. Mohamed Salem(Levine Cancer Institute)
Dr. Mark Lewis (Intermountain Health)
- Genitourinary Cancer – June 9, 6:00PM EST
Dr. Matthew Galsky (Mount Sinai)
Dr. Ashish Kamat (MD Anderson Cancer Center)
“ASCO’s Annual event is the premiere gathering of the nation’s most prominent minds in cancer research and treatment. There is no better place for LARVOL to recognize the leading influencers driving cancer research and discovery and convene expert oncologists to unpack the research findings being presented at the event,” said Bruno Larvol, LARVOL Founder & CEO. “This event also allows us to highlight the innovative platforms LARVOL is developing to enable the work and success of pharma and oncology decision makers, treatment developers, and product marketers. We are pleased to have the opportunity to participate and amplify the voices sharing important insights from the event.”
The poster session is the only ASCO sponsored event. Night at the Museum and clinical panels are hosted by LARVOL. For more information visit LARVOL.com.
LARVOL supports the data and intelligence needs of the pharmaceutical and biotech industry with expert curated information. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The VR-first, remote-always LARVOL team includes MDs, PhDs, and industry professionals around the globe who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network